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Objectives. The Liquemin in Myocardial Infarction During 
Thrombolysis With Saruplase (LIMITS) study was instituted ta 
evaluate and characterize the effect of a prcthrombolytic heparin 
bolus (5,000 IU) on the efficacy and safety of saruplase in patients 
with acute myocardial infarction. 
Background. Heparin has been used after thrombolytie therapy 
for acute myocardial infarction to prevent reocclusion of the 
infarct.related artery. 
Methods. The study was designed as a randomized, parallel- 
group, double-blind, mnlticenter trial. Patients were treated 
within 6 h of onset of symptoms with either a bolus of 5,000 IU of 
heparin (Liquemin) (n = 56, HSH group) or placebo (n = 62, 
PSH group) before thrombolytic treatment with saruplase given 
as a 20.rag bolus fol!owed by an infusion of 60 mg over 60 rain. 
Thirty minutes after completion ofthrombolysis, an intravenous 
heparin infusion was administered for 5 days. Before coronary 
angiography was performed at 6 to 12 h after start of lysis, an 
additional bolus of 5,000 IU heparin was given to all patients. End 
points tudied were patency of the infarct-related artery, changes 
in the hemostatic system and bleeding complications. 
Results. In the HSH group (heparin-saruplase-heparin), 
78.6% of patients had an open infarct-related vessel (Thrombol- 
ysis in Myocardial Infarction [TIMI] flow grade 2or 3) compared 
with 56.5% in the PSH group (placebo-saruplase--heparin) (in- 
tention-to-treat analysis, p = 0.01). No significant difference was 
observed between the two groups with regard to changes in 
fibrinogen and fibrin/fibrinogen degradation products. A total of 
eight bleeding complications (14.3%) were observed in the HSH 
group and five (8.1%) in the PSH group; no cerebrovascnlar event 
occurred, and no allergic reaction was reported. A total of 12 
patients died during the hospital stay, 3 in the HSH group (5.4%) 
and 9 in the P~tl group (14.5%). 
Conclusions. In acute myocardial infarction, the administra. 
tion of a heparin bolus before thrombolytic herapy with saruplase 
is associated with a significantly higher patency at angiography 6 
to 12 h after the start of thrombolysis without any appreciable 
increase in risk of bleeding. 
(J Am CoU Cardio11995;2&365-73) 
Heparin has been used empirically after thrombolytic therapy 
for acute myocardial infarction to prevent thrombotic reocclu- 
sion of the infarct-related coronary artery. The optimal strat- 
egy of heparin administration has not yet been determined. 
The timing and dose of heparin has varied widely in clinical 
trials but has been used as adjunctive therapy with all throm- 
bolytic agents (i.e., recombinant tissue-type plasminogen acti- 
vator [aiteplase], streptokinase, anistreplase and urokinase) in 
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the setting of acute myocardial infarction (1-7). Saruplase, a
recombinant single-chain urokinasc-type lasminogen activa- 
tor, has been tested in clinical trials (8-15) (INN [a full-length 
unglycosylated single-chain urokinase-type lasminogen acti- 
vator prepared from recombinant Escherichia coli]) (Fig. 1). In 
the current randomized, double-blind trial, an intravenous 
bolus of heparin or placebo was given immediately before 
thrombolysis with saruplase. Thirty minutes after the saruplase 
infusion was completed a continuous intravenous infusion of 
heparin was administered to all patients for 5 days and was 
titrated to maintain thrombin time at two to three times the 
control value. The trial was designed to evaluate the effect of 
adjunctive heparin on coronary patency, incidence of bleeding 
complications and hemostasis after saruplase therapy in pa- 
tients with acute myocardial infarction. 
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Figure 1. Schematic presentation of amino acid sequence of saruplase, 
single-letter code. Asterisks = active-site amino acids; arrows = 
cleavage sites into active high molecular weight two-chain uroldnase- 
type plasminogen activator der/vative (Lys 158) and low molecular 
weight derivative (Lys 135), 
Methods 
The study was a randomized placebo-controlled, parallel- 
group, double-blind trial. Fifteen local hospitals in proximity to 
the University Clinic of GOttingen, Germany, participated in 
the trial. The study protocol was. approved by the ethics 
committee of the University of Gfttingen as well as a central 
ethics and advisory board, which was specially convened for the 
study. All patients gave informed consent before ntry into the 
study. The administration ftrial medication was taken as the 
irrevocable ntry of a patient into the study. 
Inclusion criteria. Patients 20 to 75 years old with sus- 
pected acute myocardial infarction characterized by chest pain 
lasting for at least 30 rain despite oral treatmerit with nitrates 
or calcium antagonists, or both, were screened for entry. ST 
segment elevation of 0.3 mV in at least wo precordial leads or 
ST segment elevation of 0.2 mV in at least wo limb leads, or 
both, had to be present. Patients with a first or a previous 
infarction in a remote area were included. The interval be- 
tween onset of symptoms and start of infusion was not to 
exceed 6h. 
Exclusion criteria. The currently accepted contraindica- 
tions for thrombolytic therapy were used as exclusion criteria. 
In addition, patients who refused consent for coronary angiog- 
raphy, were obese or had cachexia (Broca index <70 or >130), 
administration fheparin in the previous 24 h, anticoagulation, 
cardiogenic shock, traumatic resuscitation, complete !eft bun- 
dle branch block, a cardiac pacemaker, previous coronary 
artery bypass urgery, endocarditis, acute pericarditis or atrial 
fibrillation of any origin were excluded. 
Study treatment. Unless contraindicated all patients were 
started on a nitroglycerin (3mg/h) infusion, which was titrated 
according to blood pressure and continued until oral nitrates 
could be given. One group of patients received a single 
intravenous bolus of 5,000 IU of heparin as premedication in 
blinded manner (heparin-saruplase-heparin [HSH] group). 
The second group of patients was given a corresponding 
placebo bolus (placebo--saruplase-heparin [PSH]group) (Fig. 
2). Thereafter, all patients immediately received a bolus of 
20 mg of saruplase, followed by an intravenous infusion of 
60 mg of saruplase over 60 min. An intravenous infusion of 
heparin (15 IU/kg per h) was started in all patients 30 min after 
completing the saruplase infusion and continued until the end 
of the fifth day after thrombolytic treatment. An additional 
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intravenous bolus of 5,000 IU of heparin was given before 
catheterization. Antiplatelet drugs were not allowed between 
start of thrombolysis and the end of the fifth day. Other 
medication could be given if ne, cessary. Saruplase was prepared 
by Gruenenthal GmbH, Aachen, Germany and provided in 
vials containing 10 mg of lyophilized active compound plus 
stabilizing ingredients. Heparin (Liquemin 5000) was pur- 
chased from Hoffmann-La Roche AG, Grenzach-Wyhlen, 
Germany. A corresponding matching placebo was manufac- 
tured by Gruenenthal ensuring that the study could be per- 
formed in blinded manner. 
Coronary angiography. After completion of the thrombo- 
lyric infusion patients were transferred from local hospitals to 
the catheterization laborato~j in G6ttingen so that coronary 
angiography could be performed between 6 and 12 h after the 
start of thrombolytic therapy. Standard projections were used, 
and each main coronary artery was viewed three times. Biplane 
ventriculography was also performed. Additional procedures, 
such as percutaneous transluminal coronary angioplasty or 
intracoronary l sis, were not allowed before visualization of the 
infarct-related artery. Qualitative assessment of the flow in the 
infarct-related artery was performed according to the TIMI 
grading system (16). The films were read by investigators who 
had no knowledge of the treatment: TIMI flow grades 2and 3 
were considered patent and 0 and 1 occluded. An estimation of 
the degree of stenosis of the infarct-related artery was re- 
corded. 
Hematologic studies. Blood was sampled through an in- 
dwelling needle used exclusively for this purpose. Blood sam- 
ples were taken on admission and 60 rain after starting the 
study medication. A special kit was provided to ensure uniform 
handling of samples. The first 2 ml of blood was discarded. 
After coUection of the second sample, both samples were 
centrifuged, and the plasma was frozen. The concentrations of 
fibrinogen, fibrinogen degradation products, fibrin degradation 
products and thrombiu-antithrombin III complex were as- 
sayed centrally. Routine laboratory variables were documented 
at admission and on the following day. 
Determination of infarct-specific enzyme activity, Venous 
blood samples were taken b~fore commencing thrombolytic 
therapy. Starting 60 rain after the end of the sarup~ase infusion, 
eight samples were to be taken at 2-h intervals up to 16 h, and 
a further eight samples were to be taken at 4-h intervals up to 
48 h. The samples were sent to the University Hospital of 
Figure 2. Action and therapy scheme. AMI = acute myocardial 
infarction; iv = intravenous. 
GOttingen for central assay of the actMty of creatine kinase-MB 
isoenzyme (CK-MB). 
Adverse events, electrocardiography and follow-up. Ad- 
verse events were reported as "bleeding complications" or 
"cardiovascular events" or "other adverse vents." The sever- 
ity of the event was evaluated using predefined criteria. The 
time and date of onset and duration, as well as the treatment 
required, were documented. Where possible, computer- 
assisted tomography was performed to confiz~ the diagnosis if 
intracranial bleeding was suspected. All cardiac-related ad- 
verse events were to be reported. Specific questions were asked 
about he occurrence of angina w~thout remfarct~on, "angina, 
presumably reinfarction" and "confirmed reinfarction." Stan- 
dard 12-lead electrocardiograms (ECGs) were recorded on 
admission and immediately before coronary angiography. A
central analysis of inclusion ECGs was performed to confirm 
adherence to ECG inclusion criteria. Follow-up examinations 
took place at 3, 6 and 12 months. At all three follow-up visits 
the patients' functional state was classified according to the 
New York Heart Association functional score for heart failure 
and Canadian Cardiovascular Society score for angina pecto- 
ris, both ranging from I to IV. The ECGs were recorded at 
each visit. Reinfarctions and deaths were documented. 
Statistical analysis, Because the study was designed as a 
pilot trial, no testable hypothesis was formulated. The patency 
of the infarct-related coronary artery, frequency of bleeding 
events and effects on hemostatic variables were analyzed as 
equivalent end points. Two hundred patients were considered 
sufficient o detect a difference in patency rates of 65% versus 
82% (alpha 0.05, beta 0.2). The two groups of patients tudied 
differed only in the prelysis administration of a heparin, or 
placebo to heparin, bolus. To detect poor efficacy (low patency 
rate) in the PSH group as early as posgible, a sequential 
analysis of the patency r~.tes, using discordant pairs, formed 
within each center, of patients from the two treatment groups 
was employed. This sequential nalysis was based ou the study 
of subsequent pairs of patients on different reatments within 
each center with only pairs discordant concerning patency 
being used. An interim analysis was scheduled midway through 
the study. For this analysis, patency rates were compared by 
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Table 1, Baseline Charactefistit~ 
HSH Group PSH Group 95% Confidence Limits of Difference 
(n = 56) (n = 62) (normal approximation) 
Age (30 58.6 (9.0) 59.5 (9.2) (-4.2; 2.4) 
Male (%) 83.9 83.9 ( -  13.6; 13.6) 
Weight (kg) 77.7 (11.6) 77.6 (ILl) (-0.9; 4.5) 
Height (eta) i72.4 (7.3) 170.6 (7.7) (-4.0; 4.2) 
Infarct location (%) 
Anterior 46.4 41.9 ( -  13.8; 22.9) 
Inferior 51.8 56.5 ( -  18.2; 18.8) 
Unknown 1.8 !.6 (-4.5; 5.9) 
Systolic blood pressure (ram Hg) 130 (21) 136 (21) (-13.6; 1.6) 
Heart rate (beats/rain) 74 (17) 77 (19) (-9.5; 3.5) 
Onset of symptoms to start of 2:37 (1:16) 3:08 (1:12) (-0:57; -0:04) 
saruplase infusion (h:min) 
Time from heparin/placebo olus to 8:22 (2:27) 8:01 (2:27) (-0:32; 1:14) 
corona,-y angiography (h:min) 
Where applicable, data are expressed as mean value (8D), HSH = heparin-saruplase-heparin; PSH = pla~bo- 
saruplase-heparin. 
the Fisher exact est (alpha 0.05, two-sided). All data were 
collected and analyzed centrally. An intensive query system 
was used for missing or inconsistent data. Documentation a d 
study monitoring were performed according to good clinical 
practice standards. The categoric variables are reported as 
percentage rates; mean values and standard eviations are 
used to describe continuous variables. Differences between 
treatment groups are reported by 95% confidence intervals 
(CIs). 
Results 
Interim analysis. After inclusion of the first 100 patients 
(March 1990) the results of the interim analysis were presented 
to the central ethics and advisory board. On the basis of this 
report he central ethics and advisory board decided on July 25, 
1990 to terminate the study. By this time a total of 118 patients 
had been included in the trial, the results of which are 
presented in the present report. 
Baseline characteristics and protocol compliance. Be- 
tween March 19, 1989 and June 30, 1990~ 118 patients were 
enrolled in the study (56 in the HSH group, and 62 in the PSH 
group). The two groups of patients were similar with respect to 
age, gender, height, weight, site of infarction and heart rate 
(Table 1). A difference of 31 min was found between the time 
of onset of symptoms and start of thrombolytic nfusion; and 
minor differences were found for systolic blood pressure, 
fibrinogen and fibrin degradation products. One patient in the 
PSH group had a previous infarction at the same location. In 
one patient in the HSH group, typical acute myocardial 
infarction symptoms were not confirmed. All other patients 
satisfied the inclusion criteria, and no patient had criterion for 
exclusion. In 114 patients (54 in the HSH group, 60 in the PSH 
group), myocardial infarction was confirmed electrocardio- 
graphically or enzymatically. A definite diagnosis was not 
available, in four patients. One patient in the PSH group died 
early and therefore did not undergo angiography. Ten patients 
(four in the HSH group, six in the PSH group) underwent 
coronary angiography after the 6- to 12-h time window. 
Therefore, 11 patients were classified as having occluded infarct- 
related coronary arteries for the intention-to-treat analysis. 
Angiographic findings. In 117 patients, coronary angiogra- 
phy was performed a mean of 8 h 22 rain (-+2 h 27 rain) after 
the initial heparin bolus in the HSH group and 8 h I min (+_2 h 
27 min) after the initial placebo bolus in the PSH group. 
Perfusion (TIMI flow grade 2 or 3) was present in 83.9% of 
HSH group patients and 62.9% of PSH group patients. An 
intention-to-treat analysis resulted in patency rates of 78.6% in 
the HSH group and 56.5% in the PSH group (p = 0.01) (Table 
2). The initial time difference between onset of symptoms and 
start of therapy did not explain the difference inpatency rates. 
Clinical course. Between the end of catheterization a d 
the end of hospital surveillance, 38 patier~ts underwent percu- 
taneous transluminal coronary angioplasty and 5 coronary 
Table 2. Angiographic Findings 
HSH Group PSH Group p 
Peffusion Grade (n = 56) (n = 62) Value 
Per protocol analysis (according to 
angiography performed) 
TIMI flow grade 0 + 1 16.1% 35.5% 
TIM! flow grade 2 + 3 83.9% 62.9% 
Missing 0% 1.6% 
Intention-to-treat analysis 
(angiograms outside time 
window were classified as 
occhded) 
TIMI flow grade 0 + 1 
TIMI flow grade 2 + 3 
0.02 
21.4% 43.5% 
78.6% 56.5% 0.01 
Data presented are percent of patients. TIMI = Thrombolysis inMyocardial 
Infarction; other abbreviations ~.s in Table 1. 
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Table 3. Intervention After 6- to 12-h Angiography 
HSH Group PSH Group 
Intervention (n = 56) (n = 62) 
PTCA immediately after 17 (30.4%) 21 (34.4%) 
angiography 
Pateney after PTCA 
TIMI flow grade 0 + 1 5.9% 19.1% 
TIMI flow grade 2 + 3 94 1% 80.9% 
Emergency oronary bypass urgery 3 (5.4%) 2 (3.3%) 
lntracoronary thrombolysis with 4 (7.1%) 6 (9.7%) 
urokinase (500,000 U/30 rain) 
Data presented are number or percent of patients. PTCA = coronary 
angiop!asty; other abbreviations a in Tables 1 and 2. 
artery bypass graft surgery. The patency rates after angioplasty 
were 94.1% (HSH group) and 80.9% (PSH group). Ten 
patients received intracoronary thrombolysis with urokinase 
after angiography (Table 3). Bleeding events were reported for 
eight patients (14.3%) in the HSH group and five (8.1%) in the 
PSH group. Only one patient (HSH group) required transfu- 
sion because of a puncture site hemorrhage (Table 4). There 
was no marked ifference between the two treatment groups 
with respect to incidence of recurrent infarction, arrhythmias, 
heart failure and angina pectoris at discharge. Definitive 
reinfarction occurred uring the hospital phase in three pa- 
tients (5.4%) in the HSH group and in six (9.7%) in the PSH 
group. No confirmed cerebrovascular event occurred in any of 
the 118 patients treated. Cerebral bleeding was suspected to be 
one of the possible causes of convulsion, circulatory collapse 
and subsequent death of one patient in the PSH group; 
however, the more likely cause of death was reinfarction or 
ventricular f ee wall rupture. An autopsy could not be per- 
formed. During the hospital phase there were three deaths 
(5.4%) in the HSH group and nine (14.5%) in the PSH gro,lp. 
The cause of death was cardiac related in 11 patients (heart 
failure) and unknown in 1 (PSH group). There was no sugges- 
tion or evidence of any allergic reaction occurring during the 
hospital phase in any of the patients treated. 
Cardiac enzymes. The CK-MB peak concentrations and 
area under the curve were the same in both groups. However, 
the time to CK-MB peak concentration was shorter in the 
HSH group than in the PSH group (9 h 33 rain [+5 h 36 rain] 
vs. 10 h 39 rain [+-5 h 46 mini, respectively) (Table 5). 
Coagulation and fibrinolytic analysis. There was a decline 
of fibrinogen concentrations a  a result of thrombolytic ther- 
apy, which was similar in both treatment groups (median [25%, 
75% percentile]): from 3.6 (2.8, 4.5) to 0.6 (0.1, 1.7) g/liter in 
the HSH group and from 3.1 (2.7, 4.0) to 0.9 (0.1,1.8) g/liter in 
the PSH group. As expected, the concentrations offibdnogen 
and fibrin degredation products increased similarly in both 
groups. The median thrombin--antithromhin III complex val- 
ues in the HSH group after lysis were lower than those in the 
PSH group (Table 6). 
Follow-up. Follow-up data were available for 103 patients 
at 1 year. Twelve patients died during the hospital phase and 
three during the 1-year follow-up period (cardiac-related 
events in two [PSH group], unknown events in one [HSH 
group]). The total mortality rate after 1 year was 12.7% (15 of 
118 patients). In the HSH group, the total mortality rate after 
1 year was 7.1% (4 of 56 patients), and that for the PSH group 
was 17.7% (11 of 62). The 1-year reinfarction rate after 
discharge was 1.9% for both groups. During the 1-year follow- 
up, five patients underwent bypass urgery and eight coronary 
angioplasty (four in each group). Health status according to 
Canadian Cardiovascular Society and functional classifications 
was similar in both groups after 1 year. 
Discuss ion  
The LIMITS study evaluated the 6- to 12-h patency of the 
infarct-related coronary artery rather than left ventricular 
function or survival, which are the ultimate goals of thrombo- 
Table 4. Adverse Events During Hospital Stay 
HSH Group PSH Group 95% Confidence Limits of Difference 
Adverse Event (n = 56) (n = 62) (normal approximation) 
Bleeding complications 
All 8 (14.3%) 5 (8.1%) (-5.0; 17.8) 
Puncture site 5 (8.9%) 4 (6.5%) 
Others 2 (3.6%) t (1.6%) 
Requiring transfusion 1 (1.8%) 0 
Cardiac events 
Angina, possible reinfaretion 1 (1.8%) 4 (6.5%) 
Definite reinfuretion 3 (5.4%) 6 (9.7%) (-14.0; 5.4) 
AV block, 2nd or 3rd degree 8 (14.3%) 5 (14.5%) 
Ventricular tachyeardia or fibrillation 17 (30.4%) 11 (17.7%) 
Heart failure at discharge 8 (14.3%) 12 (19.4%) 
Angina pectoris at discharge 10 (17.9%) 12 (19.4%) 
Stroke 0 0 
Death 3 (5,4%) 9 (14.5%) (-20.0; 1) 
Allergic reaction 0 0 
Data presented are number (%) of patients. AV = atrioventricular block; other abbreviations a in Table 1. 
370 TEBBE ET AL JACC Vol. 26, No. 2 
SARUPLASE AND HEPARIN IN AMI August 1995:365-73 
Table 5. Infarct-Specific Enz~ane Activity 
HSH Group PSH Group 95% Confidence Limits of Difference 
(n = 56) (n = 62) (normal approximation) 
Pretreatment CK-MB (U/liter) 10.8 (7.3) 11.6 (11.2) ( -  4.2; 2.6) 
Maximal CK-MB (U/liter) 71.8 (58) 71.1 (47.2) (-18.4; 19.6) 
Time flora onset of symptoms 9:33 (5:3b) 10:39 (5:46) ( -3:09; 0:57) 
to maximal CK-MB (h:min) 
CK-MB area under the curve 1,377 (828) 1,384 (830) (-305; 293) 
(U/liter x h) 
Data presented are mean value (SD), unless otherwise indicated. CK-MB = creatine kinase-MB isoenzyme; other 
abbreviations a  in Table 1. 
lytic therapy after acute myocardial infarction, although the 
GUSTO (28) study shows that patency can be regarded as a 
valid end point and predictor of survival. The major finding of 
this double-blind trial was that treatment with heparin fol- 
lowed by saruplase led to higher coronary patency (78.6%) 
after 6 to 12 h, whereas treatment with placebo followed by 
saruplase resulted in a patency rate of only 56.5% (p = 0.01). 
Conjunctive thrombolytic therapy. Current thrombolytic 
strategies inacute myocardial infarction have many shortcom- 
ings, including failure of recanalization within 90 min in 15% 
to 50% of patients (17); delay in the restoration of coronary 
flow (18); development of reocclusion i  5% to 15% of patients 
(7); and bleeding complications, especially intracranial bleed- 
ing, in up to 0.5% of patients (19). 
Conjunctive hepariu in mortality trials. The earliest study 
to evaluate hcparin as an adjunctive treatment tothrombolysis 
was the SCATI study (20), in which throtrbolytic therapy with 
streptokinase was given within 6 h after onset of acute myo- 
cardial infarction. The mortality rate was significantly lower 
(4.5%) in patients randomly assigned to receive postlysis 
heparin (2,000 V intravenously, followed by 12,500 U subcu- 
taneously every 12 h) compared with the control group (8.8%) 
with no heparin treatment after thrombolytic therapy. In the 
Table 6. Coagulation a d Fibrinolytic Variables 
HSH Group PSFI Group 
(n = 56) (n = 62) 
Fibrinogen (g/liter) 
Before lysis 3.6 (2.8; 4.5) 3.1 (2.7; 4.0) 
End of saruplase infusion 0.6 (0.1; 1.7) 0.9 (0.1; 1.8) 
Fibrinogen degradation 
products (rag/liter) 
Before lysis 0.5 (0.4; 0.7) 0.4 (0.4; 0.5) 
End of saruplase infusion 57.0 (13.0; 174.0) 29.5 (2.5; 230.0) 
Fibrin degradation 
products (mg/ml) 
Before lysis 0.5 (0.4; 0.7) 0.4 (0.3; 0.5) 
End of samplase infusion 13.0 (7.3; 17.0) 10.0 (7.0; 15.0) 
Thrombin-antithrombin Ill 
complex 0tg/litcr) 
Before lysis 14.6 (6.2; 43.0) 6.6 (3.1; 21.5) 
End of samplase infusion 22,0 (12.0; 70.0) 66.0 (44.0; 142.0) 
Data presented are median (25%; 75% percentile). Abbreviations a  in 
Table 1, 
GISSI-2 international trials (21,22), the same trend was seen 
among patients who received both streptokinase and heparin 
(mortality rate was 7.9% vs. 9.2% for streptokinase alone). 
These data indicate that heparin given subcutaneously two 
times/day beginning 9to 12 h after streptokinase therapy, with 
or without an intravenous bolus of heparin, is a useful adjuvant 
to str6ptokinase treatment in patients with an acute myocardial 
infarction (23). In the ISIS-2 trial (24), patients were random- 
ized to receive streptokinase or no thrombolysis. Heparin 
treatment was not part of the study protocol but was ased at 
the discretion of the physician and recorded. Patients with 
heparin (either subcutaneously or intravenously) inaddition to 
streptokinase had a lower mortality rate (8.7%) than those 
without heparin (10.1%), but these results may be biased 
because there was no randomization. The ISIS-3 trial (25) 
randomized patients with suspected acute myocardial infarc- 
tion, using a factorial design, to streptokinase, anistreplase or
recombinant tissue-type plasminogen activator (rt-PA [dute- 
plase]) and to receive 12,500 U of heparin two times/day 
subcutaneously, begun 4 h after lysis, or no heparin. All 
patients were to receive aspirin. During the heparin treatment 
period, up to day 7 there were slightly fewer deaths for aspirin 
plus heparin, but there was no significant difference in the 
35-day mortality rate for aspirin plus heparin (10.3%) versus 
aspirin alone (10.6%) (26). In the GISSI-2 international study 
group trial (21,22), the mortality rate among patients who 
received rt-PA and heparin (12,500 U subcutaneously twice 
daily, starting 12 h after lysis) was 9.2% and 8.7% among those 
who received rt-PA without heparin (p = 0.39). Finally, the 
addition of subcutaneous 5~parin to the thrombolytic regimens 
with streptokinase or rt-PA did not significantly reduce mor- 
tality compared with nonuse of heparin (27). In the GUSTO 
trial (28), there was no difference in mortality rates after 
streptokinase treatment with intravenous or subcutaneous 
heparin, b~t the accelerated rt-PA regimen combined with 
intravenous heparin (bolus dose of 5,000 U followed by a 
continuous infusion of 1,000 U/h) resulted in a 14% reduction 
in mortality rate to 6.3% compared with that after streptoki- 
nase. The accelerated rt-PA regimen with intravenous heparin 
also resulted in better patency rates (29). 
Conjunctive heparin in patency trials (Table 7). The ear- 
liest randomized controlled study evaluating the additive ffect 
of heparin on coronary patency isthe Third Thrombolysis and 
JACC Vol. 26, No. 2 TEBBE ET AL. 371 
August 1995:365-73 SARUPLA" ~ND HEPARIN IN AM1 
Table 7. Hepann in Conjunction With Thrombolysis in Randomized Patency Trials in Acute Myocardial Infarction 
Thrombolytic Control Time of 
Study (ref. no.) Agent Dosage Heparin Therapy Therapy Angiography 
Patency Rate (no. of pts) 
(TIMI flow grade 2 ot 3) 
P 
Heparin Group Control Group Value 
Topoi et al. Alteplase 1,5 mg/kg in Bolus of 10,000 U before lysis - -  
(30) 4 h 
Bleieh et al. Alteplase 100 mg in 3 h Bolus of 5,000 U within 1st 
(31) hour, then 1,000 U/h for 3 d 
Hsia et al. (32) Alteplase 100 mg in 6 h With start of lysis bolus of Aspirin 80 mg/d 
5,000 U, then 1,CO0 dha for 
7d 
de Bono et al. Alteplase 100 mg in 3 h Bolus of 5,000 U before lysis, 250-300 mg 48-120 h 
(34) then 1,000 U/h up to aspinn IV or 
angiography plus 250- PO 
300 mg aspirin IX,' or PO 
O'Connor et al. Anistreplase 30 U in 2-5 4 h after lysis 15 U/kg per h 325 mg aspirin/d Day 5 
(35) min for 24 h, 325 mg aspirin/d 
Present study Saruplase 80 mg in l h Bolus of 5,000 U before l~ois, Placebo bolus 30 6-12 h 
30 rain after lysis, 15 U/kg rain after lysis 
per h for 5 d 15 U/kg per h 
for5 d 
90 mi, 79% 79% NS 
(50/63) (54/68) 
Day 3 71% 43% 0.015 
(30/42) (19/42) 
%24 h 82% 52% <0.0001 
(82/100) (48/93) 
83.4% 74.7% <0.02 
(221/265) (1S9/253) 
80% 73% NS 
(94/1 i7) (83/114) 
78.6% 56.5% 0.01 
(44/56) (35/62) 
d = day; IV = intravenously,; PO = orally; pts = patients; ref. = reference. 
Angioplasty in Myocardial Infarction (TAMI-3) trial (30), in 
which 134 patients with acute myocardial infarction of recent 
onset (<6 h) received rt-PA (1.5 mg/kg body weight over 4 h) 
with or without an intr:~venous bolus of 10,000 U heparin. 
Coronary angiography was performed 90 min after start of 
therapy, awhen the infusion of rt-PA is still in progress, and 
showed apateney rate of 79% in both groups. It was concluded 
that early intravenous heparin does not facilitate the fibrino- 
lyric effect of rt-PA, and heparin therapy can be delayed for at 
least 90 rain after the beginning of thrombolysis with rt-PA. In 
contrast, in a trial by Bleich et al. (31), 84 patients were treated 
with 100 mg rt-PA for 3 h and were simultaneously randomized 
to receive intravenous heparin (bolus of 5,000 U, followed by 
1,000 U/h for 3 days) or no heparin. Although coronary 
angiography was performed on day 3, the patency rate was 
significantly higher in the heparin (71%) than in the nonhepa- 
rin group (43%). The Heparin Aspirin Reperfusion Trial 
(HART) (32,33) compared rt-PA plus heparin with rt-PA plus 
aspirin in ~200 patients. Patency measured by coronary an- 
giography at a mean of 18 h after start of treatment was 82% 
in the heparin group and 52% in the aspirin group (p < 
0.0001). In the Sixth European Coot~erative Study Group 
(ECSG-6) trial (34), all patients received 100 mg of rt-PA and 
aspirin and were randomized toreceive heparin or no heparin 
up to coronary angiography, which was performed between 
days 2 and 5. Patency (TIMI flow grade 2 and 3) was present 
in 83% of patients who had heparin therapy and in 75% of 
patients who did not (p -~ 0.02). The Duke University Clinical 
Cardiology Study (DUCCS-1) (35) was a randomized trial to 
evaluate the effects of heparin (15 U/kg per h, starting 4h after 
lysis) in conjunction with anistreplase on coronary patency. A
patent infarct-related artery (TIMI flow grade 2 or 3) was 
present in 80% of patients with and in 73% of those without 
heparin. At late, predischarge angiography on hospital day 5 
the difference was not significant. In general, these studies 
show that early heparin therapy during the first hours after the 
start of thrombolytic therapy results in higher patency rates. It 
is possible that the effect of heparin is different for the various 
thrombolytic agents. 
In the present study, the only difference in postinfarction 
treatment was the prethrombolytic heparin bolus before saru- 
plase. Whether the difference observed was due to the poten- 
tiaUon of action by saruplase or prevention of rethrombosis 
remains to be established. Howeve :, for alteplase the effect of 
heparin is more likely to be a reduction i  the reocclusion rate 
(36), and heparin may be replaced with an oral antiplatelet 
regimen 24 h after thrombolysis (37). 
Coagulation and fibrinolyde variables. The changes een 
in fibrinogen and in fibrin and fibrinogen degradation products 
were as expected, and the initial bolus of heparin did not 
appear to exert an influence on their concentrations However, 
pretreatment wi h heparin may have prevented the increase in 
thrombin-aatithrombin III complex levels een after saruplase 
therapy, possibly by preventing the positive feedback produc- 
tion by platelets stimulated during thrombolytic therapy or by 
inhibiting clot-localized thrombin activity reexposed by throm- 
bolysis. 
Bleeding complications. A moderate xcess of bleeding 
was reported in the heparin group (14.3%) compared with that 
in the placebo group (8.1%), but only one severe bleeding 
event occurred in each group. Because there was no marked 
difference in the fibrinogen levels between the groups, this 
cannot be attributed to a possible increase in nonspecific lytic 
action by saruplase. There may have been an increase in the 
overall ytic efficacy caused by heparin cotreatment due to the 
attenuation fthe opposing thrombotic activity of thrombin, as 
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demonstrated by the reduced TAT III levels in the heparin 
group. This reasoning is not invalidated by the excess of mild 
bleeding events in the heparin group because these predomi- 
nantly took place at puncture sites. 
Limitations ~f the study. Antiplatelet drugs were not al- 
lowed during the first 5 days of the study. Higher patency rates, 
especially in the PSH group, might have been seen had these 
drugs been given. However, although mortality rate is lowered 
with aspirin (24), to our knowledge there has been no study to 
test he effect on patency rate. At the time of the design of the 
present study, the accepted efinition of an open vessel was 
TIMI flow grade 2 or 3. A retrospective analysis of our data has 
shown that TIMI flow grade 3 was 75.0% (HSH group) and 
59.6% (PSH group). Although the magnitude of the patency 
rate is diminished, the clinical impression remains the same. 
Patients in the HSH group were treated on average 31 rain 
earlier, and it may be assumed that this contributed to the 
difference in patency rates. The patency rate for those patients 
treated within 2 h in the HSH group was 86.4% versus 84.2% 
for those treated between 2 and 3 h. For the PSH group these 
were 50.0% and 66.7%, respectively. Therefore, although there 
is a difference with time, this does not appear to have played a 
major role in the result. 
Clinical implications. The present study has important 
implications for the clinical use of saruplase because it shows 
that heparin given before the start of saruplase isnecessary for 
improved efficacy (although there is a slight tendency toward 
more bleeding). Although the purpose of this pilot trial was not 
to recruit sufficient numbers of patients to demonstrate inter- 
group differences inmortality rate, the marked increase in the 
patency rate in the heparin group may have translated into the 
observed trend to a reduced in-hospital mortality rate (5.4% 
vs. 14.5% in the placebo group) (38). On the basis of our 
findings that heparin pretreatment further improved the 
thrombolytic efficacy of saruplase without markedly increasing 
the incidence of severe adverse vents, it must now be strongly 
urged that saruplase treatr,ent always be preceded by a 
heparin bolus (5,000 ILl ii,,ravenously). 
Appendix 
LIMITS Study Group 
Steering Committee: Gi~ettingen: U. Tebbe, Chairman; Aachen: 
H. Barth, I. Boesl; Bochura: J. Windeler. Ethics and Advisory Board: 
Berlin: H. Schmutzler, Chairman; Aachen: G. Berns, B. Straeter; 
Heidelberg: J. Huebner, E. Weber; Mainz: J. Meyer; Tiibingen: H. K. 
Selbraann. Participating centers and investigators: St. Bernward Kran- 
kenhaus Hildesheim: P. Roseraeyer, H. Knauf; Evangelisches Kranken- 
haus GOttingen-Wende: M. Liwoeha, K. Wurm; Evangelisches Kranken- 
haus Holzminden: P. yon Loewis of Mortar, V. Burstedde; 
Kreiskrankenhaus Osterode: J. Kobrle; lOeiskrankenhaus Alfeld: H. D. 
Reimann, W. Lieb; Kreiskrankenhaus Eschwege: K.-H. Kroenert, E. R. 
Schwarz; Johanniter Krankenhaus Gronau: S. Hassan, O. Schumann; 
Staedtisches Krankenhaus Wolfenbuettel: P. Sehwandt, J. Neubauer; 
Kreiskrankenhaus Goslar: E. Goede, R. Klinge; Evangelisches Kranken- 
haus Bad Gandersheira: K. Erdraaun, R. Zahn; Kreiskrankenhaus 
Charlottenstifl Stadtoldendorf: J. Ebel; Vereinskrankenhaus Hannover- 
sch-Muenden: G. Andreasen, L. Kallraann; Alben-Schweitzer Kranken- 
haus Northeim: M. Bruns, P. Kleine; AIbert-Schweitzer Krankenhaus 
Uslar. A. Oltraann, W. Koehler; Krankenhaits St. Martini Duderstadt: 
T. Reiteraeier, W. Wucherpfennig. Center for statistics: Bochum: 
J. Windeler, H. J. Trarapisch, C. Schwarzweller. Central coronary 
angiography assessment: G6ttingen: J. Wojcik, M. Ashmawy, 
U. Tebbe. Central ECG assessment: Gi~ttingen: J. Wojcik, U. Tebbe. 
Central cardiac enzyme assessment: G6ttingen: M. Ashmawy, 
U. Spaar, R. Soballa. Eindhoven, The Netherlands: J. J. M. L. Hoff- 
mann. Technical and administrative support group: Aachen: I. Boesl, 
K. Steffens, R. Groves, G. R. Hopkins, H. Barth. 
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